natgillin/translations-raw huggingface dataset:
The patients enrolled in these trials had failed surgical or medical castration (e.g. luteinising hormone-releasing hormone [LHRH] agonist or gonadotropin-releasing hormone [GnRh] antagonist) therapies and had metastatic disease in the soft tissue and/or bone.
Bolniki, vključeni v ta preskušanja, so imeli neuspešno terapijo s kirurško kastracijo ali kastracijo z zdravili (npr. agonistov hormona za sproščanje luteinizirajočega hormona [LHRH, luteinizing hormone- releasing hormone] ali agonistov hormona za sproščanje gonadotropina [GnRh, gonadotropin-releasing hormone]) in metastatsko bolezen v mehkem tkivu in/ali kosteh.
The patients had an average of 1 to 4 episodes per day while taking maintenance opioid therapy.
Bolniki so ob jemanju vzdrževalnega zdravljenja z opioidi navajali v povprečju 1 do 4 epizode prebijajoče bolečine na dan.
The patients had experienced at least two relapses in the previous two years.
Bolniki so v dveh predhodnih letih imeli vsaj dva zagona bolezni.
The patients had previously been treated but the treatments had not worked or the disease had come back.
Bolniki so pred tem že bili zdravljeni, vendar to ni bilo uspešno oziroma se je bolezen ponovila.
The patients had previously taken other treatments for HIV for at least six months, but these had stopped working.
Ti bolniki so predhodno najmanj šest mesecev jemali druga zdravila proti okužbi z virusom HIV, vendar so ta prenehala učinkovati.
The patients improved following discontinuation of therapy.
Stanje bolnikovo se je po prekinitvi zdravljenja izboljšalo.
The patients in CT-AMT-010-01 have been followed for up to 5 years (n=6) post therapy administration, those in CT-AMT-011-01 for up to 5 years (n=13), and those in CT-AMT-011-02 for up to 1 year (n=3).
Pri bolnikih v študiji CT-AMT-010-01 so sledenje opravljali do 5 let (n = 6) po zdravljenju, pri bolnikih v študiji CT-AMT- 011-01 do 5 let (n = 13), pri bolnikih v študiji CT-AMT-011-02 pa do 1 leta (n = 3).
The patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks.
Bolniki v študiji so bili okuženi z genotipom 1, 2 ali 3 in so vsi prejemali zdravljenje 12 ali 24 tednov.
The patients in this study (n=452) had locally recurrent, inoperable and/or metastatic soft tissue sarcoma of one of two subtypes – leiomyosarcoma or liposarcoma.
Bolniki v tej študiji (n=452) so imeli lokalno recidiven, inoperabilen in/ali metastatski sarkom mehkih tkiv ene od dveh podvrst – leiomiosarkom ali liposarkom.
The patients included in the phase 3 trials followed a restrictive diet during the trial prescribed by a dietician and they were advised to increase their physical activity.
3. faze so med preskušanji uživali restriktivno dieto, ki jo je predpisal dietetik, in svetovali so jim , naj povečajo svojo telesno dejavnost.
The patients received Hizentra every week for 28 weeks.
Bolniki so zdravilo Hizentra 28 tednov prejemali enkrat na teden.
The patients received treatment with Yervoy (3 mg per kg bodyweight), treatment with an experimental medicine called ‘gp100’, or treatment with a combination of Yervoy and gp100.
Bolniki so vštudiji prejemali zdravilo Yervoy (3 mg na kg telesne mase), poskusno zdravilo, imenovano gp100, ali kombinacijo zdravila Yervoy in gp100.
The patients receiving the lower dose of Torisel in combination with interferon alfa survived for a similar length of time (8.4 months) as those taking interferon alfa alone.
Bolniki, ki so prejemali manjši odmerek zdravila Torisel v kombinaciji z interferonom alfa, so preživeli približno toliko časa (8,4 meseca) kot tisti, ki so prejemali samo interferon alfa.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10 – 24.
Bolniki, ki so sodelovali v študiji so imeli rezultat MMSE (kratek preizkus spoznavnih sposobnosti - Mini- Mental State Examination) 10 – 24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10-24.
Pri proučevanih bolnikih so bili rezultati MMSE (Mini-Mental State Examination – kratek preskus spoznavnih sposobnosti) med 10 in 24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10-24.
Proučevani bolniki so imeli rezultate MMSE (Mini-Mental State Examination – kratek preizkus spoznavnih sposobnosti) med 10 in 24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10–24.
Proučevani bolniki so imeli rezultate MMSE (Mini-Mental State Examination – kratek preizkus spoznavnih sposobnosti) med 10 in 24.
The patients taking 5 mg Volibris once a day could walk an average of 36 m more after 12 weeks of treatment, while the patients taking placebo could walk 9 m less.
Bolniki, ki so prejemali zdravilo Volibris v odmerku 5 mg enkrat na dan, so lahko po 12 tednih zdravljenja prehodili v povprečju 36 m več, medtem ko so bolniki, ki so prejemali placebo, prehodili 9 m manj.
The patients taking Instanyl were allowed to take a second spray ten minutes after the first dose if there had been insufficient pain relief.
Če olajšanje bolečine pri bolnikih, ki so jemali Instanyl, ni bilo zadostno, so jim deset minut po prvem odmerku dovolili vzeti še drugega.
The patients treated with micafungin in clinical studies represent a critically ill patient population that requires multiple medicinal products including antineoplastic chemotherapy, potent systemic immunosuppressants and broad spectrum antibiotics.
Bolniki, ki so se v kliničnih študijah zdravili z mikafunginom, predstavljajo izrazito bolno populacijo bolnikov, ki se je sočasno zdravila z več zdravili, vključno s kemoterapijo z zdravili z delovanjem na novotvorbe, močnimi sistemskimi imunosupresivi in širokospektralnimi antibiotiki.
The patients were distributed in three main categories: haematological failure (29%), cytogenetic failure (35%), or intolerance to interferon (36%).
Bolniki so bili razdeljeni v tri glavne kategorije: hematološki neuspeh (29 %), citogenetični neuspeh (35 %) ali neprenašanje interferona (36 %).
The patients were enrolled into a single phase I (n = 12) or two phase II (n = 14 / n = 14) safety and efficacy studies, and received multiple doses of clofarabine by intravenous infusion (see section 5.1).
Bolniki so sodelovali v eni študiji varnosti in učinkovitosti I. faze (n = 12) ali dveh študijah varnosti in učinkovitosti II. faze (n = 14 / n = 14), kjer so z intravensko infuzijo prejeli več odmerkov klofarabina (glejte poglavje 5.1).
The patients were given an Ozurdex implant or they received a ‘sham’ treatment where an applicator was pressed against their eye but nothing was actually injected.
Bolniki so prejeli vsadek zdravila Ozurdex ali pa navidezno zdravljenje, pri katerem se aplikator prisloni ob oko, vendar se dejansko ničesar ne injicira.
The patients were given either Macugen (0.3 mg, 1 mg or 3 mg) or a ‘sham’ injection.
Bolniki so prejeli zdravilo Macugen (0,3 mg, 1 mg ali 3 mg) ali navidezno injekcijo.
The patients were randomized to carbamazepine CR 400 – 1200 mg /day or levetiracetam 1000 - 3000 mg /day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400–1.200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1.000–3.000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov, odvisno od odziva.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400-1.200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1000-3000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov, odvisno od odziva.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400–1200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1000–3000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov, odvisno od odziva.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400-1200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1.000-3.000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov odvisno od odziva.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400-1200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1000-3000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov odvisno od odziva.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400–1200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1000–3000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov odvisno od odziva.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so randomizirano prejemali 400–1200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1000–3000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov, odvisno od odziva.
The patients were switched to monotherapy with miglustat 100 mg t.i.d.
Bolniki so prešli iz monoterapije z miglustatom 100 mg dvakrat na dan.
The patients were titrated to their optimal dose of rotigotine in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 8 mg/24 h over 4 weeks.
Bolnikom so odmerek 4 tedne postopno povečevali do optimalnega odmerka rotigotina v tedenskih korakih po 2 mg/24 h, od 2 mg/24 h do največjega odmerka 8 mg/24 h.
The patients were titrated to their optimal dose of rotigotine in weekly increments of 2 mg/24 h starting at 4 mg/24 h to a maximum dose of 16 mg/24 h.
Bolnikom so odmerek postopno povečevali do optimalnega odmerka rotigotina v tedenskih korakih po 2 mg/24 h, od 4 mg/24 h do največ 16 mg/24 h.
The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 6 mg/24 h.
Bolnikom so odmerek postopno povečevali do optimalnega odmerka rotigotina ali placeba v tedenskih korakih po 2 mg/24 h, od 2 mg/24 h do največjega odmerka 6 mg/24 h.
The patients were titrated to their optimal doses of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 4 mg/24 h.
Bolnikom so odmerek postopno povečevali do optimalnega odmerka rotigotina ali placeba v tedenskih korakih po 2 mg/24 h, z začetnim odmerkom 4 mg/24 h.
The patients were treated for nine or 14 weeks.
Bolnike so zdravili devet ali štirinajst tednov.
The patients were treated for one to three years and the main measure of effectiveness was based on the proportion of patients who had a stroke or a blood clot blocking blood vessels in other parts of the body each year.
Bolnike so zdravili od enega do treh let, glavno merilo učinkovitosti pa je temeljilo na deležu bolnikov, ki so vsako leto doživeli kap ali imeli krvni strdek, ki je zamašil katero koli žilo v drugih delih telesa.
The patients were treated for six months with Remicade, another medicine azathioprine, or the combination of Remicade and azathioprine.
Bolnike so šest mesecev zdravili z zdravilom Remicade, azatioprinom (drugim zdravilom) ali s kombinacijo zdravila Remicade in azatioprina.
The patients were treated until their disease got worse or the side effects of treatment became unmanageable.
Zdravljenje bolnikov je trajalo do poslabšanja bolezni ali pojava neobvladljivih neželenih učinkov.
The patients with dementia due to Parkinson’s disease taking Exelon capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Exelon, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
The patients with dementia due to Parkinson’s disease taking Prometax capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Prometax, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
The patients with dementia due to Parkinson’s disease taking Rivastigmine 1 A Pharma capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Rivastigmine 1 A Pharma, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
The patients with dementia due to Parkinson’s disease taking Rivastigmine Hexal capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Rivastigmine Hexal, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
The patients with dementia due to Parkinson’s disease taking Rivastigmine Sandoz capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Rivastigmine Sandoz, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
The patients’ average HbA1c at baseline ranged from 7.6 to 8.5% and patients were treated for at least 52 weeks.
Ob začetku zdravljenja so povprečne ravni HbA1c pri bolnikih znašale med 7,6 in 8,5 %, bolniki pa so se zdravili vsaj 52 tednov.
The patients’ bone marrow contained up to 30% abnormal cells.
Kostni mozeg bolnikov je vseboval do 30 % nenormalnih celic.
The patients’ CD4 cell counts also rose from around 280 cells/mm3 before treatment by an average of around 185 cells/mm3.
Število celic CD4 pri bolnikih se je prav tako povečalo od približno 280 celic/mm3 pred zdravljenjem za povprečno vrednost okoli 185 celic/mm3.
The patients’ condition had been stabilised by treatment with tobramycin before the study.
Pred študijo se je stanje bolnikov stabiliziralo z zdravljenjem s tobramicinom.
The patients’ HbA1c levels fell from a baseline of over 7.5% by between 1.22 and 1.64%.
Njihove ravni HbA1c so z izhodiščne vrednosti nad 7,5 % padle od 1,22 do 1,64 %.
The patients’ target date for quitting was set at one week after starting treatment and the patients were followed up for a further 40 weeks after their treatment to see if they started smoking again.
Ciljni datum opustitve kajenja je bil postavljen en teden po začetku zdravljenja, vse preizkušance pa so opazovali še nadaljnjih 40 tednov po koncu zdravljenja, da bi videli, ali so znova začeli kaditi.
The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia from glimepiride or, for example, as a result of visual impairment.
Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije povezane z glimepiridom, pa tudi npr. zaradi prizadetosti vida.
The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia.
Hipoglikemija lahko poslabša bolnikovo zmožnost koncentracije in reagiranja.
The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia.
Hipoglikemija lahko zmanjša sposobnost koncentracije in reakcijske sposobnosti bolnika.
The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia.
Zaradi hipoglikemije se lahko bolnikova sposobnost koncentracije in odzivanja zmanjša.
The patient’s airway should be maintained.
Pri bolniku je treba ohranjati proste dihalne poti.
The patient’s blood glucose (sugar) levels should be regularly tested to find the lowest effective dose.
Raven glukoze (sladkorja) v krvi bolnika je treba redno preverjati, da določimo najmanjši učinkovit odmerek.
The patient’s blood glucose (sugar) should be regularly tested to find the lowest effective dose.
Raven glukoze (sladkorja) v krvi bolnika je treba redno preverjati, da se določi najmanjši učinkoviti odmerek.
The patient’s blood glucose (sugar) should be tested regularly to find the lowest effective dose.
Raven glukoze (sladkorja) v krvi bolnika je treba redno preverjati, da se določi najmanjši učinkoviti odmerek.
The patient’s blood glucose should be tested regularly to find the lowest effective dose.
Koncentracijo glukoze v krvi bolnika je treba redno testirati, da se tako določi najmanjši učinkoviti odmerek.
The patient’s blood glucose should be tested regularly to find the lowest effective dose.
Za določitev najmanjšega učinkovitega odmerka je potrebno redno spremljati koncentracijo glukoze v krvi bolnika.
The patient’s blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels.
Pred zdravljenjem je treba preveriti bolnikove ravni belih krvnih celic, trombocitov in hemoglobina za zagotovitev, da te presegajo najnižje določene ravni.
The patient’s blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels.
Pred zdravljenjem je treba preveriti ravni belih krvnih celic, trombocitov in hemoglobina bolnika za zagotovitev, da te presegajo najnižje določene ravni.
The patient’s blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels.
Pred zdravljenjem je treba preveriti ravni belih krvnih celic, trombocitov in hemoglobina bolnika, da bi se prepričali, ali so te večje od najnižjih določenih ravni.
The patient’s blood should be monitored regularly to see how the medicine is working.
Redno je treba spremljati bolnikovo kri, da se preveri delovanje zdravila.
The Patient’s Booklet should contain the following key messages:
Brošura za bolnike mora vsebovati naslednja ključna sporočila:
The patient’s complete blood cell count must be taken before starting treatment and monitored during treatment.
Pred začetkom zdravljenja je treba opraviti pregled bolnikove krvne slike in jo med zdravljenjem nadzirati.
The patient’s condition should be evaluated continuously.
Bolnikovo stanje je treba stalno ocenjevati.
The patient’s disease should be confirmed by genetic testing whenever possible.
Kadar je mogoče, je treba bolnikovo bolezen potrditi z genetskimi preiskavami.
The patient’s eye should be disinfected and numbed with an anaesthetic before the implant is injected.
Bolnikovo oko je treba pred injiciranjem vsadka razkužiti in omrtvičiti z anestetikom.
The patient’s haemostatic functions should be screened prior to surgery.
Bolnikove hemostatske funkcije je treba preveriti pred kirurškim posegom.
The patient’s initiation dose of Bronchitol (400 mg) must be used under the supervision and monitoring of an experienced physician or another health care professional appropriately trained and equipped to perform spirometry, monitor oxygen saturation (SpO2), and manage acute bronchospasm (see sections 4.4 and 4.8) including appropriate use of resuscitation equipment.
Začetni odmerek zdravila Bronchitol (400 mg) je treba dati pod nadzorom in spremljanjem izkušenega zdravnika ali drugega zdravstvenega delavca, ki je ustrezno usposobljen in opremljen za izvedbo spirometrije, spremljanje nasičenosti s kisikom (SpO2) in obravnavo bronhospazma (glejte poglavji 4.4 in 4.8), vključno z ustrezno uporabo opreme za oživljanje.
The patient’s kidney function will be monitored regularly during treatment with Zurampic and the doctor will advise the patient to take sufficient fluid during the day and always take Zurampic with either allopurinol or febuxostat, which helps to prevent kidney damage from Zurampic.
Med zdravljenjem z zdravilom Zurampic bo zdravnik spremljal delovanje bolnikovih ledvic in mu svetoval, naj podnevi popije dovolj tekočine in naj vedno vzame zdravilo Zurampic bodisi z alopurinolom bodisi s febuksostatom, kar preprečuje poškodbe ledvic zaradi zdravila Zurampic.
The patient’s liver and bone marrow should be monitored during treatment using blood tests.
Med zdravljenjem je treba s pomočjo krvnih testov nadzorovati jetra in kostni mozeg bolnika.
The patient’s liver function should also be checked weekly for one
Delovanje jeter pri bolniku je treba prav tako preverjati enkrat tedensko en
The patient’s liver function should be checked with blood tests before treatment is started and regularly for the following 6 months.
Pred uvedbo zdravljenja in nato redno naslednjih 6 mesecev je treba s preiskavami krvi preverjati delovanje jeter pri bolniku.
The patient’s liver should be monitored before and during the treatment.
Pred zdravljenjem in po njem je treba spremljati delovanje bolnikovih jeter.
The patient’s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.4).
Pred izvedbo intravitrealnega posega je treba pozorno preveriti bolnikovo anamnezo glede preobčutljivostnih reakcij (glejte poglavje 4.4).
The patient’s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.4).
Pred izvedbo intravitrealnega postopka je treba skrbno preučiti bolnikovo anamnezo preobčutljivostnih reakcij (glejte poglavje 4.4).
The patient’s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure.
Pred izvedbo intravitrealnega posega je treba pozorno preveriti bolnikovo anamnezo glede preobčutljivostnih reakcij.
The patient’s neutrophil count should be monitored every week.
Vsak teden je treba pregledati število nevtrofilcev.
The patient’s QTc interval (a measure of the electrical activity of the heart) and certain blood values should be assessed in advance and monitored during treatment.
Pred začetkom uporabe je treba pri bolniku izmeriti interval QTc (meritev električne aktivnosti srca) in nekaterih vrednosti v krvi, ki jih je treba nato med zdravljenjem spremljati.
The patient’s response and the need for further treatment should be evaluated after three months.
Po treh mesecih je treba oceniti bolnikov odziv in potrebo po nadaljnjem zdravljenju.
The patient’s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).
Bolnikov odziv je treba spremljati in v primerih, ko ne pride do zadostne učinkovitosti, razmisliti o zvišanju odmerka (glejte poglavje 5.1).
The patient’s response to treatment and need for continued therapy should be re-evaluated on a regular basis.
Odziv bolnika na zdravljenje in potrebo po nadaljnji terapiji moramo redno ponovno ocenjevati.
The patient’s response to treatment and the need for continued pharmacotherapy should be evaluated on a regular (for example, monthly) basis (see section 5.1).
Odziv bolnika na zdravljenje in potrebo po nadaljnji farmakoterapiji je treba ovrednotiti na redni (npr. mesečni) osnovi (glejte poglavje 5.1).